Showing results (81-90 of 106) with videos related to
Sort By:
Pageof 11
Journal of Proteome Research|February 1, 2011
Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation studyMohamed I F Shariff, Asmaa I Gomaa, I Jane Cox, et al.Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|August 5, 2017
Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian ExperienceTamer Elbaz, Magdy Elserafy, Wafaa Elakel, et al.Expert Review of Gastroenterology & Hepatology|June 8, 2019
High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter studySamar K Darweesh, Kadry Elsaeed, Heba Omar, et al.Gut|April 19, 2018
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in EgyptGamal Shiha, Gamal Esmat, Mohamed Hassany, et al.British Journal of Cancer|January 27, 2017
Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasionImam Waked, Sarah Berhane, Hidenori Toyoda, et al.Journal of Hepatology|September 23, 2017
Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4Gamal Esmat, Tamer Elbaz, Maissa El Raziky, et al.Open Forum Infectious Diseases|January 23, 2018
Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care ContinuumAlastair Heffernan, Ella Barber, Nicola A Cook, et al.Journal of Viral Hepatitis|November 15, 2024
Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low- and Middle-Income CountriesRenae Furl, Kimberly K Scarsi, Harlan Sayles, et al.Expert Review of Gastroenterology & Hepatology|August 17, 2019
Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patientsShereen Abdel Alem, Aisha Elsharkawy, Wafaa El Akel, et al.Frontiers in Oncology|February 5, 2025
MiR-216a-3p inhibits the cytotoxicity of primary natural killer cellsRowan Abdelbary, Manon Ragheb, Shereen A El Sobky, et al.Pageof 11